Takeda's leuprorelin successor moves into Phase II in Japan
This article was originally published in Scrip
Executive Summary
Takeda has begun the Phase II development in Japan of TAK-385, a potential successor in the female health setting to one of its mainstay products, the gonadotropin-releasing hormone agonist leuprorelin.